Buy Dollar General for consistency and Dollar Tree for high-risk, high-reward, Jim Cramer says

Buy Dollar General for consistency and Dollar Tree for high-risk, high-reward, Jim Cramer says


CNBC’s Jim Cramer on Thursday said investors who value consistency should buy Dollar General while risk-takers should purchase Dollar Tree.

“If you want a consistent operator that doesn’t need to do anything too crazy to beat the estimates, that’s Dollar General. Even though they’re lowering prices, I think that’s a good long-term strategy to win over customers,” the “Mad Money” host said.

“Dollar Tree is more of a high-risk, high-reward turnaround play, where the stock could have a lot more upside if they pull off the execution. But if they screw up, you can kiss your gains goodbye,” he added.

Cramer said that the two companies’ contrasting pricing strategies has helped Dollar General come out on top. Dollar Tree announced late last year that it was raising the prices of most of its products to $1.25 to help offset pandemic-driven costs. 

In contrast, Dollar General said in an analyst call on March 17 that the retailer has “leaned into” its $1 products, including through plans to set up more in-store displays of items at that price point.

“While Dollar General’s pitching this as a move to help their customers, who often struggle to make ends meet, especially if they’re on a fixed income, it has the added advantage of luring away disaffected Dollar Tree customers who don’t like paying an extra quarter,” Cramer said.

Dollar General stock declined 2.13% on Thursday to $222.63. The company reported quarterly earnings in line with forecasts and a miss on revenue earlier this month. Dollar General also forecast better-than-expected full-year sales and raised its dividend by 31%.

Cramer recently highlighted Dollar General as a dividend stock to buy.

Dollar Tree stock fell 0.11% to $160.15 on Thursday, notching a new 52-week high of $162.13 earlier in the day. The company missed Wall Street expectations on revenue in its latest quarterly earnings. 

The host said that Dollar Tree stock has gained overall in recent months and highlighted the company’s executive board changes at Dollar Tree as a reason. The retailer named Richard Dreiling, a former Dollar General executive, as Dollar Tree’s executive chair earlier this month due to an activist investor campaign. 

Piper Sandler and Loop Capital Market upgraded their positions on Dollar Tree after the move. “Activist pressure can work wonders, especially if it’s a smart activist,” Cramer said.

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer Twitter – Facebook – Instagram

Questions, comments, suggestions for the “Mad Money” website? [email protected]





Source

AI will supercharge sports team valuations, says Arctos Partners’ Charles
Business

AI will supercharge sports team valuations, says Arctos Partners’ Charles

A version of this article appeared in CNBC’s Inside Alts newsletter, a guide to the fast-growing world of alternative investments, from private equity and private credit to hedge funds and venture capital. Sign up to receive future editions, straight to your inbox. The rise of artificial intelligence is likely to boost the valuations of sports teams and […]

Read More
Disney names parks boss Josh D’Amaro as its next CEO to succeed Bob Iger, effective March 18
Business

Disney names parks boss Josh D’Amaro as its next CEO to succeed Bob Iger, effective March 18

Disney has named Josh D’Amaro, chairman of Disney Experiences, as its next CEO, succeeding Bob Iger and clinching a closely watched succession race at the Mouse House. Investors, industry insiders and onlookers have long awaited the announcement of who will take over as the next leader of one of the most storied U.S. companies. The […]

Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Business

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in […]

Read More